Directed share issue and new financial targets Sales > SEK 400m by '28e and EBIT/cash flow positive by ~'27e-'28e Fund future growth, clinical trials and increased production
ANNONS
Directed share issue to fund future growth
OssDsign has carried out a directed share issue of 11.5m shares, corresponding to an increase of 11.8% in the number of shares in the company. Based on the closing price as of 3 June 2025, and before fees, this corresponds to an equity raise of approximately SEK 158m. The company states that the proceeds will be used to: 1) double the US sales force by '26e, 2) launch two new products during the ‘Strategy Period’ (2025–2028), 3) invest in clinical trials and expand the PROPEL spinal fusion registry, and 4) invest in production capacity to become more scalable and improve cost-efficiency, and 5) corporate purposes including quality assurance. If the issue is successful, the company believes it will be fully capitalised until it turns cash flow positive.
